ArticleCommunications medicine2025
Multiple sclerosis risk stratification and healthcare cost prediction using machine learning.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increasing availability of healthcare data offers an opportunity to address chronic diseases such as multiple sclerosis (MS) more proactively. We aimed to develop a machine learning (ML) approach to identify high-risk MS patients and predict their healthcare spending.
methodsWe conducted a retrospective analysis of de-identified commercial insurance claims from over 267,000 individuals (631 with MS), spanning January 2016 to June 2018. Monthly claims data were aggregated, and 72 ML regression and 63 classification models were trained to predict which patients would be in the top decile of healthcare spending over the subsequent four months. Model performance was compared with predictions based on four-month and one-month historical spending assessments.
resultsMS patients comprise less than 0.3% of the study population yet account for over 2.5% of total healthcare expenditures. In a four-month evaluation dataset, our ML models capture an average of 76.0% of the actual top-decile spending, surpassing the four-month (43.5%) and one-month (36.5%) historical methods. Notably, the ML approach identifies more individuals transitioning into high-cost status, suggesting potential utility in guiding earlier clinical decisions.
conclusionsOur proof-of-concept ML-driven framework predicts imminent high-cost MS patients more accurately than simpler, retrospectively focused approaches. These findings may inform proactive risk stratification and resource allocation strategies, though further investigation is needed to determine how best to integrate these predictions into clinical practice.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.